PanAsia Bio President Michael Xu: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Michael Xu, president of Shanghai-based PanAsia Bio, an emerging R&D-based biotech company, sat down recently with PharmAsia News' China Bureau to discuss the company's technology for drug delivery systems, mainly in PEG-based biomaterials. PEGylation is a process of attaching strands of polyethylene glycol (PEG) to molecules, mostly peptides, proteins and antibody fragments.
You may also be interested in...
SUZHOU, China - China's Yangtze delta, which includes Shanghai, Suzhou, Nanjing and Hangzhou, will be the largest CRO cluster in the world by 2015 and Shanghai will be the number one city in the world by number of scientists engaged in commercial drug discovery, Kewen Jin, GM of Charles River China, said during the BioBay Investor Forum in Suzhou Aug. 28
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).